Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats
Biocon Biologics remains committed to global standards of quality and compliance
The transaction is part of a broader agreement with Bureau Veritas covering its worldwide food laboratory testing activities
The site’s GMP Certification has been successfully renewed
The primary objective of the study is to assess the safety and tolerability of SUVN-I6107 by monitoring adverse events (AEs), clinical laboratory, vital signs and electrocardiographs
Inaugurates new facilities to further NIMHANS’ mission of delivering cutting-edge care in mental health and neurosciences
Thyrocare becomes first national diagnostic chain with 100% of its labs with NABL accreditation
Subscribe To Our Newsletter & Stay Updated